Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Quarterly results
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/27/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LIVE FILING",
"Teva Announces Exclusive Launch of a Generic Version of Reyataz ® in the United States Jerusalem, December 27, 2017— Teva Pharmaceutical Industries Ltd., today announced the exclusive launch of a generic version of Reyataz ®1 capsules in the U.S. Atazanavir sulfate capsules are a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection for patients 6 years and older weighing at least 15 kg. “The exclusive launch of our generic version of Reyataz marks our fifth generic product offering for the treatment of HIV-1 infection,” said Brendan O'Grady, Executive Vice President, North America Commercial at Teva. “Antiviral medications continue to be a focus for Teva Generics, and this is an important addition to our portfolio.” With ..."
12/18/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LIVE FILING",
"FDA Accepts Biologics License Application for Fremanezumab with Priority Review for Prevention of Migraine and Grants Fast Track Designation for Cluster Headache Development Program"
12/15/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LIVE FILING",
"Teva Announces Exclusive Launch of Generic Viread ® in the United States Jerusalem, December 15, 2017— Teva Pharmaceutical Industries Ltd., today announced the exclusive launch of generic Viread ®1 tablets 300 mg in the U.S. Tenofovir disoproxil fumarate tablets are a nucleotide analog HIV-1 reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older. Additionally, tenofovir disoproxil fumarate tablets are an HBV reverse transcriptase inhibitor, indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older. “Currently, 1.1 million people in the U.S are living with HIV 2 and an estimated 850,000 to 2.2 million have chron..."
12/14/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"TEVA Announces Restructuring Plan and Additional Measures to improve its Business and Financial Performance",
"Employee Letter"
12/13/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LIVE FILING",
"Teva to Host Conference Call to Discuss Restructuring Plan and Additional Measures to Improve Its Business and Financial Performance at 8:00 a.m. ET on December 14, 2017"
12/12/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LIVE FILING",
"On December 12, 2017, Dr. Yitzhak Peterburg,"
12/11/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LIVE FILING",
"TEVA ANNOUNCES EXCLUSIVE LAUNCH OF GENERIC VIAGRA ® TABLETS IN THE UNITED STATES"
11/29/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LIVE FILING",
"The New England Journal of Medicine Publishes Data from Pivotal Phase III Trial of Fremanezumab for the Preventive Treatment of Chronic Migraine"
11/27/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LIVE FILING",
"TEVA ANNOUNCES NEW ORGANIZATION STRUCTURE AND LEADERSHIP CHANGES Jerusalem, November 27, 2017 - Teva Pharmaceutical Industries Ltd. announced today a new organization and leadership structure aimed to achieve better commercial focus and drive value creation. The new structure will enable strategic alignment across the portfolio, across regions and between functions, leveraging scale, enhancing agility, extracting efficiencies and providing increased proximity to the markets. This new structure will be implemented effective immediately. Kåre Schultz, Teva's President and CEO, said, “Teva is taking decisive and immediate action to address external pressures and internal inefficiencies. Our new company structure will enable stronger alignment and integration between R&D, operations and t..."
11/02/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LIVE FILING",
"Teva Announces Completion of Plan B One-Step ® Divestiture to Foundation Consumer Healthcare"
11/02/2017 6-K Quarterly results
Docs: "TEVA PHARMACEUTICAL INDUSTRIES LIMITED 6-K",
"Teva Reports Third Quarter 2017 Financial Results"
11/01/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LIVE FILING",
"Teva Announces Completion of PARAGARD ® Divestiture to CooperSurgical"
10/31/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LIVE FILING",
"TEVA WINS GENERIC UCERIS ® PATENT TRIAL Jerusalem, October 31, 2017 - Teva Pharmaceutical Industries Ltd., today announced that the United States District Court for the District of Delaware has ruled in the Company's favor in patent litigation involving Teva's abbreviated new drug application directed to a generic version of Valeant's Uceris tablets. At trial in May, the Court found that Plaintiffs did not meet the threshold to establish infringement, and the Court has now issued its written decision confirming that Teva's ANDA product does not infringe the asserted patent. “We are pleased to have another legal win on one of our first-to-file PIV patent challenges brought in through the Actavis Generics acquisition.” said Dipankar Bhattacharjee, President and CEO, Global Generic Medicines,..."
10/26/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LIVE FILING",
"Teva to Highlight Asthma Data at the 2017 American College of Allergy, Asthma and Immunology Annual Scientific Meeting"
10/19/2017 6-K Quarterly results
10/17/2017 6-K Quarterly results
10/10/2017 6-K Quarterly results
10/04/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LIVE FILING",
"Teva Comments on Anticipated At-Risk U.S. Launch of Generic Glatiramer Acetate 40mg/mL and Launch of Generic Glatiramer Acetate 20mg/mL Jerusalem, October 4, 2017 - Teva Pharmaceutical Industries Ltd. today commented that any launch by Mylan of a generic version of COPAXONE 40mg/ml prior to final resolution of the pending patent appeals and other patent litigation should be considered an “at-risk” launch, which could subject Mylan to significant damages among other remedies. Additionally, Mylan also announced approval of a generic glatiramer acetate 20mg/mL."
09/25/2017 6-K Quarterly results
09/25/2017 6-K Quarterly results
09/19/2017 6-K Quarterly results
09/19/2017 6-K Quarterly results
09/18/2017 6-K Quarterly results
09/18/2017 6-K Quarterly results
09/14/2017 6-K Quarterly results
09/12/2017 6-K Quarterly results
09/11/2017 6-K Quarterly results
09/11/2017 6-K Quarterly results
09/11/2017 6-K Quarterly results
09/06/2017 6-K Quarterly results
09/05/2017 6-K Quarterly results
08/30/2017 6-K Quarterly results
08/18/2017 6-K Quarterly results
08/07/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LIVE FILING",
"Teva Announces FDA Approval of QVAR ® RediHaler™ Inhalation Aerosol"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy